First CUH patient in national Covid-19 Trial
Cambridge University Hospitals NHS Foundation Trust has today (Friday, 27 March) enrolled its first patient into a national trial aimed at identifying treatments for Covid-19.
The Randomised Evaluation of Covid-19 Therapy (RECOVERY) Trial, led by Oxford researchers, will test several medications that are safely used for other conditions, and have shown promise in other countries.
The opportunity to join this trial will be offered to adults who are hospitalised with Covid-19 at Addenbrooke's, and other participating NHS hospitals across the country, and who do not have health conditions that would interact with the trial drugs.
There are three drugs being tested in the first stages of the trial, including hydroxychloroquine, which is similar to a drug used to treat malaria. However, the trial follows an adaptive design, which means that if further drugs show promise, they can be added to this trial.
The trial results will be regularly reviewed so that any treatments that are found to be effective can be made available to all patients.
For more information visit: CUH News
Published March 27, 2020
Latest from CCTU
National Patient Led Research Hub celebrates tenth anniversary
A national team based in Cambridge are celebrating ten years of helping people living with rare diseases to develop their own research ideas. The hub has…
Hope for MS patients as Cambridge trial suggests drug combination may repair nerve damage
Early findings from a clinical trial in Cambridge suggest a combination of metformin, a diabetes drug, and clemastine, an antihistamine, can help repair…
Prospective study into controversial brain cyst syndrome is world first
The world’s first study of its kind highlights the potential value of surgery to treat a specific kind of brain cyst that blights the lives of patients.
